Briacell Presentations Highlight Positive Clinical Data For Bria-IMTTM At ASCO 2026

(MENAFN - GlobeNewsWire - Nasdaq) Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 ...